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Background. Hepatitis C virus (HCV), a major cause of morbidity and mortality, is common and rising among young persons who 
inject drugs (PWID). Reducing the level of viremia may be an intervention, yet the impact of viremia on HCV transmission is unknown.
Methods. We conducted a prospective study of injecting partnerships (Partner Study) of young adult (age < 30 years) PWID 
within the UFO Study, which enrolled those at risk for HCV or with seronegative viremic infection and up to 3 HCV RNA–positive 
regular injecting partners. We examined the level of HCV viremia and stage of infection in the HCV-positive partner in regression 
analyses of HCV transmission events that were corroborated via HCV phylogenetic linkage analyses.
Results. We enrolled 69 at-risk/acutely infected PWID. There were 25 new HCV infections (incidence rate, 35.9 per 100 per-
son-years; 95% confidence interval [CI], 24.3–53.2 per 100 person-years); 12/25 (48%) were phylogenetically linked to at least 1 
partner. We found no association between the infected partner’s quantitative level of HCV viremia and likely transmission in multi-
variate analyses (adjusted odds ratio [AOR], 0.90; 95% confidence interval [CI], 0.55–1.46); however, seronegative viremic infection 
in the infected partner was associated with increased transmission (AOR, 28.02; 95% CI, 5.61–139.95).
Conclusions. The HCV viremia level was not associated with increased odds of transmission, yet acute HCV infection (seroneg-
ative viremic) was. Explanations include high-risk behavior during acute infection or missed fluctuations in viremia during acute 
infection. Both point to the need for frequent testing to detect new infection and attempt to prevent onward transmission.
Keywords.  acute hepatitis C infection; hepatitis C virus; injecting partnerships; phylogenetic linkage.
Hepatitis C virus (HCV) transmission is common and rising 
among young adult people who inject drugs (PWID) [1, 2]. Despite 
the implementation of services designed to prevent transmission of 
blood-borne infections in urban areas [3], the HCV incidence in 
PWID in several North American cities has remained high over the 
past 15 years; it is 25 per 100 persons-years in young adult PWID 
in San Francisco [4]. In nonurban areas in the United States, HCV 
incidence is on the rise among young adult PWID [5, 6], in tandem 
with the national opioid epidemic.
Strategies to combat the HCV epidemic among PWID include 
providing sterile injecting equipment and medication-assisted 
therapy [1, 7, 8]. In addition, as direct-acting antiviral agents 
(DAAs) that have high cure rates (>90%), reduced treatment 
time, and few side effects [9–12] have become available, treat-
ment as prevention (TaSP) has been proposed as an important 
step toward HCV elimination [13, 14]. Another vital approach 
to combat the HCV epidemic is the development of a vaccine. 
Vaccines may provide protection against infection, or more 
likely, in the case of HCV, prevent chronic infection or decrease 
the level of viremia during acute infection [15–17]. However, it 
is unknown whether the level of HCV viremia is associated with 
injecting-related transmission of HCV, although mother-to-
child transmission of HCV is associated with level of maternal 
HCV viremia [18]. HCV viremia is highest during acute infec-
tion, most notably during the period of infection when HCV 
antibodies (anti-HCV) are not detectable [19]. Thus, we aimed 
to determine the role of HCV viremia on HCV transmission.
We conducted a longitudinal study to detect new HCV 
infections within at-risk young adult PWID in injecting part-
nerships. We previously found that young PWID have a large 
number of injecting partners [20]; therefore, we used viral 
sequencing and phylogenetic analyses to provide further evi-
dence for suspected HCV transmission events within injecting 
partnerships. We aimed to determine whether the level of vire-
mia in the source partners was associated with increased HCV 
transmission to the at-risk partners and examined other part-
nership characteristics previously associated with HCV trans-
mission, including the infection phase of the infected partner 
(HCV-seronegative viremic vs HCV-seropositive viremic). We 
controlled for partnership characteristics previously associated 
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with HCV transmission such as partnership type (sexual activ-
ity yes vs no), age difference between partners, and injecting 
behaviors such as frequency of injecting together and needle/
syringe and injecting equipment sharing within partnerships.
METHODS
Study Participants
The Partner Study is a substudy of the UFO Study, a prospec-
tive cohort study of incident HCV and natural history of early 
infection [21]. Participants were enrolled in the Partner Study 
from 2006 through 2017; enrollment was not continuous due to 
funding breaks. Eligibility for the UFO Study included self-re-
ported current injecting (past 30  days, confirmed by demon-
strating knowledge of injecting procedures), being under age 
30 years, having the ability to provide informed consent, being 
fluent in English, having no plans to leave San Francisco, and 
self-reporting not being HCV RNA positive at baseline. UFO 
Study participants who reported injecting drugs with another 
person during study interviews were invited to bring their cur-
rent injecting partner(s) for Partner Study screening. Eligibility 
criteria for the Partner Study included reporting regularly 
injecting together in the same space in the prior month (≥5 
times in the prior month for pre-2015 enrollees, ≥3 times in 
the prior month for enrollees in 2015 or after). Partnerships 
were eligible for the UFO Partner Study if they were discor-
dant on HCV RNA or if they were HCV RNA concordant 
(both positive), with at least 1 of the partners recruited in the 
HCV-seronegative viremic phase of HCV infection (Table 1). 
The partner who was HCV RNA negative or in the seronegative 
viremic phase is referred to as the “at-risk partner.” For the pur-
poses of data analysis, when both partners presented with early 
acute infection (n = 3), the partner interviewed first was labeled 
the at-risk partner. In addition, because the at-risk partner was, 
by definition, either  HCV RNA negative or within the sero-
negative viremic phase, we enrolled several (16) at-risk partners 
who were HCV RNA negative but HCV antibody (anti-HCV) 
positive, suggestive of previous spontaneous clearance of HCV 
infection. The HCV RNA–positive partner was called the 
“index partner.” At-risk participants were allowed to be enrolled 
with up to 3 index partners at 1 time, and new partners could be 
enrolled at any time (with a maximum of 3 concurrent partners 
per at-risk participant). All participants were asked to individu-
ally complete monthly visits for 6 months, with active partner-
ships re-enrolled for another 6 months.
Laboratory Measures
Incident HCV infection in at-risk partners was detected at 
baseline (HCV-seronegative viremia) and subsequently (via 
HCV RNA and/or anti-HCV) via quarterly antibody and RNA 
testing. Plasma samples were tested for HCV RNA using a nu-
cleic acid amplification test (Procliex HIV-1/HCV assay, Gen-
Probe Inc., San Diego, CA, and marketed by Novartis Vaccines 
& Diagnostics, Emeryville, CA). Anti-HCV was tested at a com-
mercial lab on samples obtained by venipuncture (HCV ver-
sion 3.0 ELISA test system; Ortho Clinical Diagnostics) before 
2012, and with anti-HCV rapid testing (OraSure Technologies, 
Bethlehem, PA) starting in 2012. These tests have been shown 
to be highly concordant [22]. Quantitative HCV viremia was 
measured for the index partners at Partner Study entry and 
approximately yearly thereafter using the Bayer HCV RNA 
branched DNA assay (Versant HCV 3.0; Bayer Diagnostics, 
Tarrytown, NY) before 2011, and the Hepatitis C Virus RNA 
Quantitative Real-Time PCR (ARUP Laboratories, Salt Lake 
City, UT) starting in 2011; the latter detects higher levels of 
virus in some genotypes [23, 24]. HCV genotypes for newly 
identified infections and their index partners were determined 
by Hepatitis C Viral RNA Genotype LiPA (Quest Diagnostics, 
San Jose, CA).
HCV Amplification, Sequencing, and Phylogenetic Analysis
HCV RNA was isolated from plasma using the QIAamp Viral 
RNA Mini Kit (Qiagen) for both partners, collected closest 
to the first visit where HCV viremia was detected, in pairs in 
which the genotype matched. Viral RNA was reverse-tran-
scribed and amplified using up to 3 different primer sets. An 
amplicon approximately 3.2  kb in length covering Core to 
NS2 was attempted, as was a 389-bp fragment of the NS5B 
region. If amplification was unsuccessful, a smaller region of 
the HCV genome encompassing the HVR1 was attempted. 
Complete details on primers and PCR conditions used for 
Core to NS2 and HVR1 have been described by Tully et al. 
[23], and complete details on NS5B have been described by 
Murphy et al. [25]. Samples that successfully amplified were 
Table 1. HCV Status of Participant and Recruited Partner (n = 101 Partnerships) at the Time of UFO Partner Study Recruitment
UFO Participant HCV Status
HCV Naïve (Anti-HCV- 
and HCV RNA-)
Cleared HCV (Anti-HCV+ 
and HCV RNA-)
Chronic HCV (Anti-HCV+  
and HCV RNA+)
Acute HCV (Anti-HCV-  
and HCV RNA+) Total
HCV naïve (anti-HCV- and HCV RNA-) Not eligible Not eligible n = 29 n = 1 n = 30
Cleared HCV (anti-HCV+ and HCV RNA-) Not eligible Not eligible n = 13 n = 3 n = 16
Chronic HCV (anti-HCV+ and HCV RNA+) n = 38 n = 7 Not eligible n = 3 n = 48
Acute HCV (anti-HCV- and HCV RNA+) n = 0 n = 0 n = 4 n = 3 n = 7
Total n = 38 n = 7 n = 46 n = 10 n = 101
Abbreviation: HCV, hepatitis C virus.
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multiplexed and sequenced on an Illumina MiSeq platform, 
using a 2×250-bp V2 reagent kit. Paired-end reads obtained 
from Illumina MiSeq were subjected to stringent quality 
control and filtering and assembled into an HCV consen-
sus sequence using the VICUNA de novo assembler soft-
ware [26] and finished with V-FAT, as previously described 
[27, 28]. Maximum likelihood phylogenetic trees were con-
structed with the robustness of the resulting tree, assessed by 
bootstrapping with 1000 replicates, and clusters were iden-
tified with a bootstrap threshold of 90% and a maximum 
genetic distance threshold of 0.05.
Study Variables
The UFO Study conducted quarterly structured interviews with 
all participants. Variables included person-level characteris-
tics (gender, age, race). Partnership-level structured interviews 
were conducted monthly for each partner separately and in-
cluded past month partnership injecting behaviors (receptive 
syringe sharing, ancillary injecting equipment sharing, number 
of days injected together, number of other injecting partners) 
and sexual exposures. For behavioral variables, we used the 
responses of the at-risk partner.
Statistical Analyses
We calculated the overall incidence of HCV infection within 
at-risk partners using person-time methods. We categorized 
HCV transmission within partnerships as follows: group 1: “no 
transmission event” for partnerships in which no new HCV in-
fection occurred in the at-risk partner, that is, no HCV trans-
mission; group 2: “corroborated HCV transmission event” for 
partnerships in which the at-risk partner became infected with 
HCV or was recruited during the HCV-seronegative viremic 
phase, and the viral sequences from both partners were phylo-
genetically linked; group 3: “new HCV infection, transmission 
not corroborated” for partnerships in which the at-risk partner 
become infected during the study or was in the early acute in-
fection phase at recruitment, but the viral sequence of the new 
HCV infection was not phylogenetically linked with that of the 
enrolled partner or the HCV genotypes differed between the 
partners; and group 4: “new HCV infection, sequence not de-
termined” for the small number (4) of partnerships in which 
a new HCV infection occurred during the study, but phyloge-
netic linkage could not be determined due to insufficient mate-
rials available for sequencing for 1 or both of the partners. We 
present proportions and medians (with interquartile ranges 
[IQRs]) for at-risk partner characteristics, partnership char-
acteristics, and partnership behaviors (at Partner Study enroll-
ment), overall and by transmission category.
To examine the characteristics associated with corroborated 
HCV transmission events within partnerships, we conducted 
generalized estimating equation logistic regressions with robust 
standard errors, to account for multiple visits per partnership, 
to approximate a Cox model. We used all available at-risk 
partner visits, with the outcome variable coded as 0 for visits 
occurring before new HCV infection for all outcome groups 
and 1 for the first visit for which the HCV transmission event 
was detected. All visits for which the at-risk partner was HCV 
RNA negative were included, whereas we dropped the visits 
occurring after new HCV infection was identified and those 
visits for which and after new HCV infections were identified 
for which phylogenetic linkage was not determined (ie, group 
4) or there was no match to the putative partner (ie, group 3). 
Demographic and partnership characteristic variables (index 
race/ethnicity and age, age difference between partners, gender 
composition of partnership, duration of partnership, whether 
the index partner was in the HCV-seronegative viremic phase) 
were time invariant, whereas partnership injecting behavior 
variables (frequency of injecting, receptive needle sharing, 
ancillary equipment sharing, sex with partner, number of other 
injecting partners) were updated for each at-risk partner visit in 
the regression analyses.
Because the index partner’s HCV viremia level (analyzed as 
a log10 transformation) was measured approximately yearly, 
rather than at each study visit, and because the study visits for 
partners were not required to be on the same day, we used the 
level of viremia at the most recent index partner visit if the visit 
occurred within 2.5 months of the at-risk partner visit. To fill in 
for missing levels of viremia, we conducted the analysis using 
a last value carried forward approach for the level of index 
partner viremia, thus allowing all visits described above to be 
included (n = 509 visits). We conducted sensitivity analyses that 
included only visits for which the partner HCV viremia level 
was available within 2.5 months of the at-risk partner visit.
We further constructed a multivariable regression model of 
phylogenetically corroborated HCV transmission events, in-
cluding HCV viremia, the main exposure of interest, as well as 
variables that were associated with HCV transmission in the 
bivariate analyses (P <  .10), as above. Partner viremia was in-
cluded using last-value carried forward, as above, and we ad-
ditionally conducted a sensitivity analysis using only visits 
for which the partner level of viremia was measured within 
2.5  months of the at-risk partner visit. In addition, because 
early acute HCV infection status of the partner was likely to be 
correlated with HCV viremia [19], we constructed additional 
models removing the former variable. Lastly, we ran the multi-
variable model removing the partnerships in which both part-
ners were enrolled during the HCV-seronegative viremic phase 
to determine the impact of including these participants on the 
parameter estimates.
RESULTS
Sixty-nine persons enrolled as at-risk participants, with a 
median of 1 HCV-infected index partner per at-risk partner 
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(range, 1–9), for a total of 101 partnerships; 62 were HCV RNA 
negative, and 7 were in the HCV-seronegative viremic phase. 
Of those who were RNA negative, 14 were anti-HCV positive, 
indicating prior cleared infection.
Among the 69 at-risk participants, there were 25 new HCV 
infections (including the 7 persons who enrolled in the HCV-
seronegative viremic phase and 6 of the 14 who enrolled as 
cleared infections), for an overall HCV incidence rate of 35.9 
per 100 person-years (95% confidence interval [CI], 24.3–53.2). 
Among these 25, 20 (80%) were matched by genotype to at least 
1 of their HCV-infected partners, whereas 5 did not match any 
partner’s genotype and thus did not undergo sequencing and 
were grouped with those with no phylogenetic linkage. Of the 
20 with at least 1 genotype-matched partner, 12 were phyloge-
netically linked, and thus likely transmissions. Thus, the pro-
portion of newly identified infections with a phylogenetically 
linked HCV transmission event was 12/25 (48%).
Partnerships (n = 101) were followed for a median (IQR) of 6 
(2–11) months; partnership characteristics are described overall 
and by group in Table 2. The 25 new HCV infections occurred 
among 40 partnerships (allowing for more than 1 partner per 
at-risk participant), and there were 61 partnerships with no 
new infection (group 1). Of the 40 partnerships with new infec-
tions, HCV transmission was corroborated in 12 (group 2), 24 
were not phylogenetically matched (group 3), and 4 were not 
determined (group 4). Of note, 3 new infections occurred in 
partnerships in which both partners were in the seronegative 
viremic phase, and all 3 of these were corroborated transmis-
sions. The proportion of partnerships with a phylogenetically 
linked HCV transmission was 11.7% (12/101).
In regression analyses, we found no difference in the level of 
HCV viremia on the odds of having a corroborated transmis-
sion event (OR, 1.03 per log10 difference; 95% CI, 0.69–1.53) 
(Table 3). However, having an index partner who was in the 
HCV-seronegative viremic (acute infection) phase was asso-
ciated with significantly higher odds of a transmission event 
(OR,  14.84; 95% CI, 2.77–79.48), as was injecting more days 
together in the past month (per injecting day OR,  1.11; 95% 
CI, 1.05–1.18), always sharing ancillary injection equipment 
(OR,  4.87; 95% CI, 1.45–16.35), being male in a partnership 
with a female (OR, 7.12; 95% CI, 1.14–44.44), and being in a 
sexual relationship with one’s partner (OR, 9.74; 95% CI, 2.40–
39.48). In multivariable analyses, index partners in the HCV-
seronegative viremic phase (AOR, 28.02; 95% CI, 5.61–139.95), 
injecting more days together in the past month (AOR, 1.07; 95% 
CI, 1.01–1.14) per day of injecting together), and always shar-
ing injection equipment (AOR, 5.32; 95% CI, 1.25–22.70) were 
independently associated with increased odds of corroborated 
transmission events. In sensitivity analyses, we found no sub-
stantive differences in the results using viral load measurements 
within a window of 3  months (compared with last value car-
ried forward), nor when the HCV infection phase of the index 
Table 3. Unadjusted and Adjusted ORs for Phylogenetically Corroborated Transmission Events vs no Transmission (GEE Analyses) Among 101 Prospectively 
Followed Young PWID Partnerships
Characteristic Unadjusted OR (95% CI) Adjusted OR (95% CI)
Demographics (at enrollment)
Race of at-riska partner = nonwhite 0.52 (0.15–1.84)  
Age of at-riska partner 1.01 (0.86–1.19)  
Age difference of partnership, y 0.93 (0.84–1.03)  
Gender composition of partnership   
 Male/male or female/female Ref Ref
 Male at-riska/female indexb 7.12 (1.14–44.44)  1.91 (0.17–21.10)
 Female at-riska/male indexb 1.97 (0.50–7.84)  0.29 (0.01–6.33) 
Duration of partnership, mo 0.97 (0.95–1.01)  
Injecting and sexual behaviors (time updated)   
No. of days the partners injected together, past month 1.11 (1.05–1.17) 1.07 (1.01–1.14)
Any receptive needle sharing by at-riska partner with indexb partner, prior month = yes 1.44 (0.14–14.82)  
Ancillary equipment sharing at all instances of the partners injecting together, prior month = yes 4.87 (1.45–16.35) 5.32 (1.25–22.70)
Median No. of other injecting partners of the at-riska partner 1.01 (1.00–1.03)  
Partners had sexual relationship, prior month = yes 9.74 (2.40–39.48)  7.77 (0.58–103.52)
HCV characteristics of indexb partner (time updated)   
Indexb partner in HCV-seronegative viremic phasec 14.84 (2.77–79.48)  28.02 (5.61–139.95)
HCV viremia of indexb partner nearest visit (log10) 1.03 (0.69–1.53)d  0.90 (0.55–1.46)d
Bold indicates statistical significance (P < .05).
Abbreviations: CI, confidence interval; GEE, generalized estimating equation; HCV, hepatitis C virus; OR, odds ratio; PWID, people who inject drugs.
aAt-risk partner: enrolled as either HCV RNA negative or HCV-seronegative viremic.
bIndex partner: enrolled as HCV RNA positive.
cHCV-seronegative viremic phase: indicated by anti-HCV-negative and HCV RNA–positive test results, as well as RNA-positive test results.
dLast value carried forward.
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partner variable (HCV-seronegative viremic phase yes/no) was 
removed. Results for when both partners enrolled in the early 
acute infection phase were excluded also yielded similar results, 
although the confidence intervals were wide.
CONCLUSIONS
We conducted a prospective study that followed young adult 
PWID injecting partnerships for new HCV infection, leverag-
ing phylogenetic sequencing to provide evidence for the trans-
mission within the partnerships. We did not observe increased 
odds of transmission among partnerships by the viremia level 
of the index partner, but instead found higher odds of transmis-
sion if the index partner was in the HCV-seronegative viremic 
phase (acute infection).
We had hypothesized that the HCV viral load of the index 
partner would be associated with increased risk of transmis-
sion to the at-risk partner, as has been shown for HIV [29, 
30]. Although we found no increase in odds of transmission in 
association with quantitative level of viremia, having an index 
partner in the acute seronegative viremic phase was associated 
with significantly increased odds of transmission. This finding 
suggests that HCV transmissions occur in rapid succession, 
in which multiple PWID become infected at once, possibly 
before HCV infection is detectable via anti-HCV testing. It 
is possible that HCV infectivity is higher during this period 
due to the lack of neutralizing antibody response very early in 
infection, as is the case for HIV [31]. This suggests that while 
biomedical approaches such as TasP [13, 14, 32] and vac-
cines [33] have the potential to reduce HCV transmission by 
reducing community viral load, behavioral and testing inter-
ventions to reduce exposure to HCV during early infection 
are needed as well [3]. The lack of an association with HCV 
viral load, despite this positive finding in association with 
acute infection period, may be related to the low frequency of 
viremia testing in the positive partners [34] and the dynamic 
nature of HCV viremia in early infection [35], which hindered 
our ability to measure actual viremia near the time of trans-
mission. Previous studies have shown that the frequency of 
viremia testing can vastly impact study findings, leading to 
underestimates of HCV transmission [34].
In either case, the results suggest that scaling up HCV test-
ing of young adult PWID is urgently needed, including testing 
that includes the detection of viremia during the seronegative 
acute phase of infection [1]. Upstream approaches to reduce 
injecting of drugs, including with widespread provision of 
medication-assisted therapy [8], and overall injecting risk may 
also be useful, given that we found that within partnerships, the 
number of days injecting together and engaging in ancillary 
equipment sharing were additional independent risk factors for 
corroborated transmission events.
This study has strengths and limitations to note. Although 
other studies have examined HCV sequences and phylogenetic 
clustering among PWID with HCV [36–39], and 1 study com-
pared the overlap of phylogenetic clustering and PWID social 
networks [40], we not aware of any studies that have prospectively 
detected and corroborated transmission events within injecting 
partnerships identified a priori. The study is limited by the small 
number of partnerships, averaging 1 per month of active study 
time. The small number may be due to high levels of HCV con-
cordance within drug-using partnerships, as reported in another 
study of PWID in San Francisco [41]. We included people who 
had previously cleared HCV (ie, anti-HCV positive but HCV 
RNA negative) and became re-infected, which may have impacted 
our incidence rate. However, it is unlikely that the HCV incidence 
rate was elevated by including those participants, as studies have 
shown that reinfection incidence is lower than primary infection 
incidence [42, 43]. In addition, we were not able to corroborate 
transmission or conclude no transmission within 4 partnerships 
with new HCV infection detected, because the level of vire-
mia in the available sample was too low to conduct genotyping 
or sequencing, further limiting the sample size. Due to expense, 
we were able to measure the viral load in the index partner only 
approximately 1 time per year. As noted above, this limitation 
means that the level of viremia used in the analysis may not have 
reflected the level of viremia in the index at the time of transmis-
sion, masking a possibly real association. Lastly, all the behavioral 
variables were self-reported, and we used the responses of the 
at-risk partner in the analyses. In a previous analysis of Partner 
Study data, we found high concordance between injecting part-
ners in reporting partnership characteristics including being in a 
sexual relationship, but low concordance on injecting risk behav-
ior questions [44], which may have biased our results.
In summary, the odds of transmission were not related to 
level of HCV viremia but were greatly increased for those whose 
partners were in the seronegative viremic infection phase. These 
findings suggest that HCV transmission may happen in bursts 
of high risk, perhaps with partners other than regular injecting 
partners, that are difficult to pinpoint even with careful longi-
tudinal study. The implications are that interventions to end the 
HCV epidemic in PWID will need to be broad enough to reduce 
community viral load and injecting in general, because sporadic 
periods of behavioral risk that co-occur with new infection are 
likely to escape more targeted interventions.
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